Taysha Gene Therapies Prices Public Offering
Analysis based on 10 articles · First reported Jun 24, 2026 · Last updated Jun 25, 2026
The public offering by Taysha Gene Therapies is expected to provide significant capital, which could positively impact its ability to fund ongoing research and development of its gene therapies. This influx of capital may be viewed favorably by investors as it strengthens the company's financial position, potentially leading to increased investor confidence in Taysha Gene Therapies' future prospects.
Taysha Gene Therapies, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at $6.00 per share and 833,333 pre-funded warrants at $5.999 per pre-funded warrant. The offering is expected to generate approximately $200.0 million in gross proceeds for Taysha Gene Therapies, before deducting underwriting discounts and commissions. The company also granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock. The offering is managed by Jefferies, Goldman Sachs & Co. LLC, Piper Sandler Companies, Cantor, and Baird (investment bank), and is expected to close around June 26, 2026. The funds are intended to support the company's development of AAV-based gene therapies for severe monogenic diseases of the central nervous system.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard